These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18240853)

  • 1. Long-term efficacy of ADHD pharmacotherapy in children.
    Gilchrist RH; Arnold EL
    Pediatr Ann; 2008 Jan; 37(1):46-51. PubMed ID: 18240853
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A symposium on Attention Deficit Hyperactivity Disorder (ADHD). Developments in treatment.
    Levy F
    Aust N Z J Psychiatry; 2002 Aug; 36(4):477-9. PubMed ID: 12169142
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for adult ADHD.
    Adler LA
    J Clin Psychiatry; 2009 May; 70(5):e12. PubMed ID: 19552859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
    Simon N; Rolland B; Karila L
    Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What exactly are the benefits of stimulants for ADHD?
    Advokat C
    J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
    [No Abstract]   [Full Text] [Related]  

  • 8. Attention deficit/hyperactivity disorder across the lifespan.
    Wilens TE; Biederman J; Spencer TJ
    Annu Rev Med; 2002; 53():113-31. PubMed ID: 11818466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG
    Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention deficit hyperactivity disorder and substance use disorders.
    Szobot CM; Bukstein O
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.
    Faraone SV; Biederman J; Wilens TE; Adamson J
    Psychol Med; 2007 Dec; 37(12):1743-52. PubMed ID: 17349106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulant treatment for ADHD may not increase risk of substance abuse.
    Harv Ment Health Lett; 2008 Jun; 24(12):7. PubMed ID: 18946888
    [No Abstract]   [Full Text] [Related]  

  • 13. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.
    Wilens TE; Faraone SV; Biederman J; Gunawardene S
    Pediatrics; 2003 Jan; 111(1):179-85. PubMed ID: 12509574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood.
    Wilens TE; Dodson W
    J Clin Psychiatry; 2004 Oct; 65(10):1301-13. PubMed ID: 15491232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.
    Biederman J; Wilens T; Mick E; Spencer T; Faraone SV
    Pediatrics; 1999 Aug; 104(2):e20. PubMed ID: 10429138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.